Pharmacist monitoring of QTc interval-prolonging medications in critically iii medical patients: A pilot study

Annals of Pharmacotherapy

Volumn 42, Issue 4, 2008, Pages 475-482

  Ng, Tien M H ^a   Bell, Adrienne M ^b   Hong, Chandra ^c   Hara, Jill M ^d   Touchette, Daniel R ^e   Danskey, Karine N ^a   Lindsay, Tanya T ^a   Puumala, Susan E ^f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c VA New York Harbor Healthcare Center   (United States)

^d HUNTINGTON MEMORIAL HOSPITAL   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Critical care; Pharmacist intervention; QTc interval prolongation; Torsade de pointes

Indexed keywords

ADULT; ALGORITHM; ARTICLE; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG MONITORING; ELECTROCARDIOGRAM; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; INCIDENCE; INFORMATION PROCESSING; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PHARMACIST; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT PROLONGATION; STATISTICAL SIGNIFICANCE; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CRITICAL ILLNESS; FEMALE; HUMANS; INTENSIVE CARE UNITS; LONG QT SYNDROME; MALE; MIDDLE AGED; PATIENT CARE TEAM; PHARMACEUTICAL PREPARATIONS; PHARMACISTS; PHARMACY SERVICE, HOSPITAL; PILOT PROJECTS; PROFESSIONAL ROLE; PROSPECTIVE STUDIES;

EID: 42049107709     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K458     Document Type: Article

References (25)

1. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) U. Guidance for industry E14: clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs, 2005. www.fda.gov/cber/gdlns/ iche14qtc.htm (accessed 2005 Dec 1).
2. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA 2003;289:2120-7.
3. Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 2003;23: 881-908.
4. Ng TM, Olsen KM, McCartan MA, Speidel KM, Miller MA. Pharmacologic predictors of QTc prolongation in the adult intensive care unit (abstract). Crit Care Med 2004;32:A40.
5. Reiffel JA, Appel G. Importance of QT interval determination and renal function assessment during antiarrhythmic drug therapy. J Cardiovasc Pharmacol Ther 2001;6:111-9.
6. Schumock GT, Butler MG, Meek PD, Vermeulen LC, Arondekar BV, Bauman JL. Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy 2003;23:113-32.
7. Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999;282:267-70.
8. Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med 2006;166:955-64.
9. Woosley R. Drugs that prolong the QT interval and/or induce torsades de pointes ventricular arrhythmia. Tuscon: Arizona Center for Education and Research on Therapeutics. The Critical Path Institute. www.torsades.org (accessed 2004 Mar 1).
10. Zhou SH, Wong S, Rautaharju PM, Karnik N, Calhoun HP. Should the JT rather than the QT interval be used to detect prolongation of ventricular repolarization? An assessment in normal conduction and in ventricular conduction defects. J Electrocardiol 1992;25(suppl):131-6.
11. Bureau of Labor Statistics. National occupational employment and wage estimates, United States, 2006. Washington, DC: Bureau of Labor Statistics, 2006.
12. Faber TS, Zehender M, Just H. Drug-induced torsade de pointes. Incidence, management and prevention. Drug Saf 1994;11:463-76.
13. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol 2007;22:39-43.
14. Choy AM, Lang CC, Chomsky DM, Rayos GH, Wilson JR, Roden DM. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation 1997;96:2149-54.
15. Takanaka C, Ogunyankin KO, Sarma JS, Singh BN. Antiarrhythmic and arrhythmogenic actions of varying levels of extracellular magnesium: possible cellular basis for the differences in the efficacy of magnesium and lidocaine in torsade de pointes. J Cardiovasc Pharmacol Ther 1997; 2:125-34.
16. Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003;73:292-303.
17. Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 2006;11:52-6.
18. Samaha FF. QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin. Am J Med 1999;107:528-9.
19. Basyigit I, Kahraman G, Ilgazli A, Yildiz F, Boyaci H. The effects of levofloxacin on ECG parameters and late potentials. Am J Ther 2005;12: 407-10.
20. Milberg P, Hilker E, Ramtin S, et al. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes. J Cardiovasc Electrophysiol 2007;18:647-54.
21. Montazeri M, Cook DJ. Impact of a clinical pharmacist in a multidisciplinary intensive care unit. Crit Care Med 1994;22:1044-8.
22. Dooley MJ, Allen KM, Doecke CJ, et al. A prospective multicentre study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals. Br J Clin Pharmacol 2004;57:513-21.
23. Anderson ME. QT interval prolongation and arrhythmia: an unbreakable connection? J Intern Med 2006;259:81-90.
24. Shah RR. Drug-induced QT dispersion: does it predict the risk of torsade de pointes? J Electrocardiol 2005;38:10-8.
25. Gandhi PJ, Menezes PA, Vu HT, Rivera AL, Ramaswamy K. Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient. Am J Health Syst Pharm 2003;60:2479-83.